Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
March 16, 2021

Coronavirus company news summary – Moderna starts Phase I study of next-gen vaccine mRNA-1283 – Takeda/IDT Biologika to support production of single-shot J&J vaccine

By Chris Lo

Moderna has dosed the first patients in a Phase I study of mRNA-1283, the company’s next-generation Covid-19 vaccine candidate. mRNA-1283 is a potential refrigerator-stable vaccine that is designed to allow easy distribution and administration across settings, especially in developing countries. The safety and immunogenicity of mRNA-1283 will be assessed in this Phase I dose-ranging study.

Japanese biopharma giant Takeda has announced a mutual agreement with IDT Biologika, a contract development and manufacturing organisation, to use its capacity previously reserved for Takeda’s dengue vaccine, TAK-003, to produce the single-shot Covid-19 vaccine developed by Janssen Pharmaceutical Companies. The capacity will be returned to Takeda for critical production of its dengue vaccine after three months.

Fulgent Genetics, a technology company, has been awarded a contract by the US Centres for Disease Control and Prevention (CDC) to provide genomic sequencing of SARS-CoV-2 samples on a continuous basis by leveraging the company’s next-generation sequencing (NSG) capabilities. As per the agreement, Fulgent will sequence the genomes of random Covid-19 samples. Fulgent will use its NGS platform and sequencing data to perform a large-scale genomic survey of the virus using random samples from across the US.

Related Companies

Content from our partners
Extractables and leachables analysis in pharmaceutical quality control
How Hengst helped to keep Germany’s charity “star singers” shining
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy